Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib

Transplant International

Volumn 26, Issue 8, 2013, Pages

  Koch, Martina ^a   Gräser, Christian ^a   Lehnhardt, Anja ^a   Pollok, Jörg M ^a   Kröger, Nikolaus ^a   Verboom, Murielle ^b   Thaiss, Friedrich ^a   Eiermann, Thomas ^a   Nashan, Björn ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

anti HLA antibodies; bortezomib; combined liver kidney transplantation; rituximab; splenectomy

Indexed keywords

BORTEZOMIB; EVEROLIMUS; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ARTICLE; CASE REPORT; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SENSITIZATION; SINGLE DRUG DOSE; SPLENECTOMY;

ANTI-HLA ANTIBODIES; BORTEZOMIB; COMBINED LIVER-KIDNEY TRANSPLANTATION; RITUXIMAB; SPLENECTOMY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; PLASMAPHERESIS; PYRAZINES; SPLENECTOMY;

EID: 84880256037     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12120     Document Type: Article

References (28)

1. Susal C, Opelz G,. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269.
2. Mizutani K, Terasaki P, Hamdani E, et al,. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
3. Olausson M, Mjornstedt L, Norden G, et al,. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130.
4. Neumann UP, Lang M, Moldenhauer A, et al,. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001; 71: 1163.
5. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al,. Progressive graft fibrosis and donor-specific HLA antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333.
6. Musat AI, Agni RM, Wai PY, et al,. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500.
7. O'Leary JG, Kaneku H, Susskind BM, et al,. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection post-liver transplant. Am J Transplant 2011; 11: 1868.
8. Askar M, Schold JD, Eghtesad B, et al,. Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation 2011; 91: 1286.
9. Lehnhardt A, Dunst F, van Husen M, et al,. Elevated serum levels of B-cell activating factor in pediatric renal transplant patients. Pediatr Nephrol 2012; 27: 1389.
10. Fung J, Makowka L, Tzakis A, et al,. Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc 1988; 20: 88.
11. Taner T, Gandhi MJ, Sanderson SO, et al,. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504.
12. McMillan RW, Gelder FB, Zibari GB, Aultman DF, Adamashvili I, McDonald JC,. Soluble fraction of class I human histocompatibility leukocyte antigens in the serum of liver transplant recipients. Clin Transplant 1997; 11: 98.
13. Dar W, Agarwal A, Watkins C, et al,. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841.
14. Steinhoff G, Wonigeit K, Pichlmayr R,. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394.
15. Broome U, Glaumann H, Hultcrantz R, Forsum U,. Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand J Gastroenterol 1990; 25: 54.
16. Willicombe M, Brookes P, Sergeant R, et al,. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172.
17. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
18. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al,. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
19. Susal C, Ovens J, Mahmoud K, et al,. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a collaborative transplant study report. Transplantation 2011; 91: 883.
20. Vega J, Goecke H, Carrasco A, et al,. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate. Clin Exp Nephrol 2011; 15: 308.
21. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
22. Morath C, Beimler J, Opelz G, et al,. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506.
23. Tzvetanov I, Spaggiari M, Jeon H, et al,. The role of splenectomy in the setting of refractory humoral rejection after kidney transplantation. Transplant Proc 2012; 44: 1254.
24. Everly MJ, Everly JJ, Susskind B, et al,. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
25. Paterno F, Shiller M, Tillery G, et al,. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526.
26. Sureshkumar KK, Hussain SM, Marcus RJ, et al,. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol 2012; 77: 246.
27. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP,. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402.
28. Perry DK, Burns JM, Pollinger HS, et al,. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.